Rocephin Articles
Russia's Rafarma Pharmaceuticals increases product range
11 April 2013
13.7% growth for Indian pharma recorded 13.7%to $9.43 billion in first three quarters of fiscal 2009-10
4 February 2010
Roche in deal with moksha8 for Mexico
22 May 2009
Pfizer charged over Trovan Nigeria deaths
4 June 2007
Beximco starts selling generics to Ghana
9 April 2007
Targanta's oritavancin shows preclinical promise
9 April 2007
UPDATE: ICAAC 2006 sees strong data on next-gen antibiotics: Tygacil, ceftaroline, cethromycin
9 October 2006
Strong efficacy data for S-P's Avelox
9 October 2006
Bayer's Avelox "as effective" as potent combo regimen for CA pneumonia
11 September 2006
New Indian drug price cuts of 10%-70%
26 June 2006
Pfizer denies Nigeria trials were illegal
15 May 2006
S-P announces positive Avelox study data
17 April 2006
APP gets FDA ANDA OK for ceftriaxone
20 February 2006
Baxter gets FDA go ahead for Ceftriaxone
5 September 2005
Hospira ships first order of ceftriaxone
1 August 2005
Lupin launches generic anti-TB drugs in USA
1 August 2005
Hospira ships first order of ceftriaxone inj
25 July 2005
Roche disappoints despite 116% net income hike
7 February 2005
Tokyo pharma stocks - week to July 5
12 July 2004
Bayer continues to focus on anti-infectives
10 May 2004
Roche beats forecasts with pharma sales up 13% in first 9 months
27 October 2003
Tokyo pharma stocks - week to July 28
4 August 2003
Stock Commentary - Tokyo
30 June 2003
Tokyo pharma stocks - week to June 23
30 June 2003
Lupin files challenge to Roche's Rocephin in USA
29 April 2002
Cubist hit by missed endpoint in Cidecin trial.
21 January 2002
Merck gets US approval for new carbapenem antibiotic
30 November 2001
Pfizer's one-day Zithromax course squeaks through FDA advisory panel
12 November 2001
Pfizer sued over Trovan trials
3 September 2001
French price cuts for GSK, Lilly, Merck drugs
16 August 2001
Dip in 1st-qtr pharma sales at Roche
11 April 2001
Net income leaps 50% at Roche in 2000, but pharma sales disappoint
28 February 2001
Acquisitions to solve weak Roche pipeline?
15 January 2001
Roche names GSK's Abercrombie to heard N Amer pharma ops
12 January 2001
Cubist licenses oral ceftriaxone
30 November 2000
China sees over-supply, low demand for drugs
16 March 2000
Chinese joint-venture sales in 1999
22 February 2000
First approval for B-MS' Tequin heats up antibiotic sector - update
30 December 1999
P&U to file NDA for linezolid by year-end, new Phase III data
29 September 1999
Roche 1st qtr sales up 4%; Xenical doing well
15 April 1999
Bioject - one step ahead in a needle-free world
10 February 1999
Local demand boosts Indian pharma firms
2 February 1999
New US CDC otitis media treatment guidelines
26 January 1999
Analysts not surprised by Roche results
15 January 1999
Roche Sales Soar In 1st Quarter 1998
7 April 1998
Roche's Rocephin Approved In USA
15 January 1998
Max-GB To Double Penicillin Output
4 December 1997
FDA C'tee OKs Roche's Rocephin
26 November 1997
Chinese Sales of Joint-Venture Drugs Growing
26 September 1997
First-Quarter Sales At Roche Up 18%
21 April 1997
Antibiotic Effects Differ In Sepsis
23 September 1996
UK Industry Code of Practice Review
8 July 1996
Effects of Genomics On Antibacterial R&D
20 November 1995
Roche Ahead Of Forecasts in 1995 First Half
4 September 1995
South Korean Trade In Pharma Tech
14 November 1994
Roche Agrees To Rocephin Settlement But Denies Liability
12 September 1994
CUF REPORT ON ROCEPHIN
27 June 1994
ITALIAN DRUG FIRMS SLAM GOVT PRICE MOVES
9 May 1994
RISING SWISS FRANC HITS ROCHE SALES
18 April 1994
SALES SURGE FOR SOME DRUGS IN ITALY
14 March 1994
ROCHE COUNTERFEIT PROBLEMS IN MEXICO
7 March 1994
ROCHE RECORDS 11% INCREASE IN '93 SALES
17 January 1994
HOFFMANN-LA ROCHE'S ROCEPHIN
15 November 1993
WORLD MARKET FOR ANTI-INFECTIVES
15 November 1993
VARIABLE RESISTANCE WITH CEPHALOSPORINS
8 November 1993
CEFTRIAXONE AND SICKLE CELL
16 August 1993
ROCHE PHARMA HEALTHY IN 1st HALF
19 July 1993
ROCHE FORESEES GOOD OUTLOOK FOR 1993
3 May 1993
ROCHE LAUNCHES TWO PRODUCTS IN UK
12 April 1993
ZENECA ANTIBIOTIC IN MENINGITIS STUDY
5 April 1993
NEW DIRECTOR AT ROCHE NEDERLANDS
22 March 1993
CONTAMINATION IN ROCHE DRUGS
25 January 1993
ROCHE 1992 SALES RISE BY 13%
18 January 1993
GLOBAL DRUG MARKET: 30 YEARS OF GROWTH
4 January 1993
RESISTANCE ENSURES AUGMENTIN'S FUTURE
15 June 1992
ROCEPHIN CURES HEART INFECTIONS
18 May 1992
ROCHE'S STRONG 1st QTR GOOD FOR 1992
11 May 1992
ROCHE SEES SALES INCREASE 19% IN 1991
20 January 1992
Showing 1-92 of 92 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
